Danish committee does not recommend reimbursement for Novo Nordisk's Wegovy

The Danish pharmaceutical firm’s obesity drug is too expensive, says the Danish Reimbursement committee according to a domestic media.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by mikkel aabenhus hemmingsen, translated by daniel pedersen

The price for Novo Nordisk’s new obesity drug, Wegovy, is not equal to its therapeutic effect, assesses the Danish Reimbursement Committee, which advises the Danish Medicines Agency.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading